Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 1:17:1323-1327.
doi: 10.2147/DDDT.S281626. eCollection 2023.

The Application of Dupilumab to Pediatric Patients Aged 6-11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Sarah Balboul  1 , Julia Kahn  1 , Alexis Tracy  2 , Anjelica Peacock  3 , Abigail Cline  2   3   4
Affiliations
Review

The Application of Dupilumab to Pediatric Patients Aged 6-11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far

Sarah Balboul et al. Drug Des Devel Ther. .

Abstract

Background: While dupilumab has shown efficacy in improving atopic dermatitis, few studies have assessed the long-term clinical data of dupilumab use in pediatric patients.

Objective: In the present study, we reviewed the current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric populations.

Methods: Using PRISMA guidelines, the authors searched PubMed/MEDLINE and Embase for studies related to dupilumab treatment for atopic dermatitis in pediatric patients aged 6-11 years old.

Results: A total of 512 pediatric patients (ages 6-11) were included. Outcome measures assessed by EASI, SCORAD, P-NRS, IGA and C-DLQI showed significant improvements in scores from those observed at baseline to the last treatment of dupilumab. Most reported adverse effects on dupilumab were conjunctivitis and infection site reactions. All studies reported that dupilumab was well-tolerated.

Limitations: Limitations include the low number of studies available and observation periods of up to 16 weeks, which may be too short to evaluate the drug's effectiveness and occurrence of adverse effects. This also limits our knowledge on whether there are sustained benefits and/or diminished efficacy as well as long-term side effects.

Conclusion: Thus far, the data demonstrates dupilumab to be safe and effective in the management of moderate-to-severe atopic dermatitis in children aged 6-11 years. Future studies should evaluate long-term dupilumab use and sustained effects.

Keywords: atopic dermatitis; dupilumab; pediatric; pediatric dermatology.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts or competing interests to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023 - DOI - PMC - PubMed
    1. Goh MS, Yun JS, Su JC. Management of atopic dermatitis: a narrative review. Med J Aust. 2022;216(11):587–593. doi:10.5694/mja2.51560 - DOI - PubMed
    1. Huang AH, Roh YS, Sutaria N, et al. Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States. J Am Acad Dermatol. 2021;85(4):893–900. doi:10.1016/j.jaad.2021.03.016 - DOI - PubMed
    1. Russo F, Santi F, Cioppa V, et al. Meeting the needs of patients with atopic dermatitis: a multidisciplinary approach. Dermatitis. 2022;33(6s):S141–S143. doi:10.1097/der.0000000000000907 - DOI - PubMed
    1. Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159–162. doi:10.1136/adc.76.2.159 - DOI - PMC - PubMed

MeSH terms